Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
MedStar Health, which has 10 hospitals in Maryland and Washington DC, is now part of the Caris Centers of Excellence for Precision Medicine Network.
The firms will measure the health and economic impact of the Caris Molecular Intelligence panomic tumor profiling service for cancer patients.
WCC will help develop standards of care and best practices for integrating molecular profiling into cancer care.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.